Sheldon Ng joins CRA's life sciences practice as VP

10 July 2023 1 min. read
More news on

Sheldon NG has joined management consultancy Charles River Associates (CRA) as a vice president in its life sciences practice.

Based in San Francisco, Ng has nearly 20 years of experience supporting life sciences clients with strategic planning – including market assessments, portfolio management, asset development, and global operations. He has expertise in multiple therapeutic areas.

He joins CRA from LifeSciences Consultants, where he spent three years as a partner. Before that, he was a partner at Navigant (now Guidehouse) and VP and head of strategy and analytics at Locust Walk, an investment bank focusing on the life sciences industry.

Ng also previously held VP roles at consulting firms Promidian and Health Advances. Earlier in his career, he spent eight years at IMS Consulting Group, where he was an engagement manager in the brand and commercial strategy offering.

Sheldon Ng joins CRA's life sciences practice as VP

Ng began his career in biotech and pharma research, holding roles at Exelixis and Novartis Vaccines and Diagnostics.

He has an MBA from Northwestern University and a bachelor’s degree in biological sciences from Cornell University.

“Sheldon brings an innovative and analytical approach to his work,” said Gregory Bell, PhD, group VP and life sciences practice leader. “Over the course of his career, he’s shown a keen ability to conduct creative and socially sensitive engagements that inspire clients and yield measurable results.”

CRA’s life sciences practice supports biotech, medical device, and pharma companies, as well as law firms, regulatory agencies, and industry associations. The practices provides consulting in corporate, brand, and portfolio strategy; pricing and market access; policy; and litigation.

CRA is headquartered in Boston and has more than 900 employees across offices in the Americas, Europe, and Australia. The firm advises on business strategy, performance, and economic and financial matters pertaining to litigation and regulatory proceedings.